Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that Sun Pharmaceutical Industries, Inc., a subsidiary of the Company, has entered into licensing agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases. Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties.

The above information is a part of company’s filings submitted to BSE.